Atypical antipsychotics and metabolic syndrome. Issue 4 (December 2015)

• Record Type: Journal Article
• Authors: Perez Rodriguez, Abigail; Tajima-Pozo, Kazuhiro; Lewczuk, Adrian; Montañes-Rada, Francisco
• Is Part Of: Cardiovascular endocrinology. Volume 4:Issue 4(2015:Dec.)
• Publication Date: 2015-12
• Subjects: atypical antipsychotics -- glucose homeostasis -- metabolic syndrome -- weight gain; Cardiovascular system -- Diseases -- Periodicals; Endocrine glands -- Diseases -- Periodicals; Endocrinology -- Periodicals; Cardiovascular Diseases -- Periodicals; Endocrine System Diseases -- Periodicals; Cardiovascular system -- Diseases; Endocrine glands -- Diseases; Endocrinology; Periodicals; 616.1
• DOI: 10.1097/XCE.0000000000000063
• Languages: English
• ISSNs: 2162-688X

Abstract

Abstract : Atypical antipsychotics have become the gold standard and the first treatment option for mental illness in recent years. However, despite all the benefits provided by these drugs, a growing collection of case reports and clinical trials describing metabolic complications and body weight gain have been reported. Among atypical antipsychotic drugs, olanzapine and clozapine appear to have the highest tendency to disturb glucose metabolism compared with the other antipsychotic drugs available on the market.